Operator: Good day, and thank you for standing by. Welcome to REGENXBIO s Third Quarter 2023 Earnings Conference Call. At this time, all participants are in a listen-only mode.
ABBV-RGX-314 continues to be well tolerated in 50 patients from dose levels 1 and 2 (Cohorts 1-3) with no drug-related serious adverse events Dose level 2.
REGENXBIO Inc. (NASDAQ:RGNX – Get Free Report) shares shot up 6.7% on Wednesday . The stock traded as high as $13.81 and last traded at $13.75. 360,336 shares changed hands during mid-day trading, a decline of 8% from the average session volume of 392,987 shares. The stock had previously closed at $12.89. Wall Street Analyst […]
I’m partial to small and midsize stocks, and I especially like the size that’s right on the border between them. “Large” in the stock market these days means $10 billion or more in market value, by my classification. Midsize stocks are $1 billion to $10 billion, and small stocks are